Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
VKTX has been in the news recently: Viking Therapeutics (VKTX) has faced a bearish outlook from investors with significant funds. This sentiment contrasts with recent market movements of other companies, such as Opendoor Technologies' stock rising by 7%.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
